TD Cowen 46th Annual Health Care Conference March 3, 2026 2:30 PM ESTCompany ParticipantsJohn Jacobs - President, CEO ...

Novavax’s modeled fair value has been reset to US$13.78 from US$13.11, a small move that still matters if you are tracking how assumptions are shifting. Behind that change, recent Street research ...

Feb 26 (Reuters) - Novavax ⁠raised ⁠its adjusted revenue forecast for ⁠2026 on Thursday, banking on milestone payments from ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, ...

Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered ...

Novavax Inc (NVAX) reports a 65% revenue increase and secures major partnerships, despite facing regulatory uncertainties and strategic challenges.

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed ...

Sanofi is leading commercialization efforts for Nuvaxovid and Novavax is eligible to receive ongoing tiered royalties from sales of the vaccine. A full 12-month commercial cycle under Sanofi’s control ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal would funnel crucial ...

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...

The deal will support Gavi’s goal to fully vaccinate 50 million more children against the disease by 2030. Credit: Gavi. UNICEF and Gavi, the Global Alliance for Vaccines and Immunisation now known as ...